Aardvark Therapeutics AARD
NASDAQ AARD
$1.58 -0.01 (-0.63%)
As of: Nov 12, 2026 · 9:30 AM EST

Aardvark Therapeutics (AARD) Return on Capital Employed [ROCE] (2025 - 2026)

Updated

Aardvark Therapeutics' Return on Capital Employed [ROCE] came in at -88.42% for Q2 2026, down 59.64 percentage points from -28.79% a year earlier and down 10.82 percentage points from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Return on Capital Employed [ROCE] (2025 - 2026) Analysis & Trends

For FY2025, Aardvark Therapeutics' Return on Capital Employed [ROCE] was -72.27%.

  • Business Quant data shows AARD's Return on Capital Employed [ROCE] at -77.60% (Q1 2026), -54.71% (Q4 2025) and -41.25% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Aardvark Therapeutics 29.98 Mn -43.92 Mn - -88.42%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -88.42%
Mar 31, 2026 -77.60%
Dec 31, 2025 -54.71%
Sep 30, 2025 -41.25%
Jun 30, 2025 -28.79%
Mar 31, 2025 -27.93%
API Access

Aardvark Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=AARD&period=max&api_key=YOUR_API_KEY